Enoxaparin reduces cerebral edema after photothrombotic injury in the rat

Haemostasis

Volumn 28, Issue 2, 1999, Pages 78-85

  Pratt, J ^a,b   Boudeau, P ^a   Uzan, A ^a   Imperato, A ^a   Stutzmann, J M ^a  

^a CNS Research   (France)

^b SANOFI   (France)

Author keywords

Cerebral edema; Cerebral ischemia; Enoxaparin; Low molecular weight heparins; Rat

Indexed keywords

ENOXAPARIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULANT THERAPY; ARTICLE; BRAIN EDEMA; BRAIN ISCHEMIA; BRAIN WATER; CONTROLLED STUDY; DOSE RESPONSE; HEMOGLOBIN DETERMINATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; WATER CONTENT;

ANIMALS; BRAIN EDEMA; ENOXAPARIN; FIBRINOLYTIC AGENTS; FLUORESCENT DYES; INJECTIONS, INTRAVENOUS; INTRACRANIAL EMBOLISM AND THROMBOSIS; MALE; RATS; RATS, SPRAGUE-DAWLEY; ROSE BENGAL;

EID: 0032463477     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Buckley MM, Sorkin EM: Enoxaparin. A review of its pharmacology and clinical applications in the prevention and treatment of thromboembolic disorders. Drugs 1992;44:465-497.
2. Bachmann F: Anticoagulants et agents thrombolytiques; in Schorderet M, et al (eds): Pharmacologie. Paris, Frison-Roche, 1989, chap 20.
3. Cade JF, Buchanan MR, Boneu B, Ockelford P, Cater CJ, Cerskus AL, Hirsh J: A comparison of the antithrombotic and haemorrhagic effects of low molecular weight heparin fractions: The influence of the method of preparation. Thromb Res 1984;35:613-625.
4. Bara L, Bloch MF, Zitoun D, Samama M, Collignon F, Frydman A, Uzan A, Bouthier J: Comparative effects of enoxaparin and unfractionated heparin in healthy volunteers on prothrombin consumption in whole blood during coagulation, and release of tissue factor pathway inhibitor. Thromb Res 1993;69:443-452.
5. Young E, Cosmi B, Weitz J, Hirsh J: Comparison of the non-specific binding of unfractionated heparin and low molecular weight heparin (enoxaparin) to plasma proteins. Thromb Haemost 1993;70:625-630.
6. Libersan D, Khalil A, Degenais P, Quan E, Delorme F, Uzan A, Latour J-G. The low molecular weight heparin enoxaparin limits infarct size at reperfusion in the dog. Cardiovasc Res 1998;37:656-666.
7. Watson BD, Dietrich WD, Busto R, Wachtel MS, Ginsberg MD: Induction of reproducible brain infarction by photochemically initiated thrombosis. Ann Neurol 1985;17:497-504.
8. Choudhri TF, Hoh BL, Solomon RA, Connolly ES, Pinsky DJ: Use of a spectrophotometric hemoglobin assay to objectively quantify intracerebral hemorrhage in mice. Stroke 1997;28:2296-2302.
9. Frydman A, Bara L, Le Roux Y, Woler M, Chauliac F, Samama MM: The antithrombotic activity and pharmacokinetics of enoxaparin, a low molecular weight heparin, in humans given single subcutaneous doses of 20 to 80 mg. J Clin Pharmacol 1988;28:609-618.
10. Nagy Z, Kolev K, Csonka E, Pék M, Machovich R: Contraction of human brain endothelial cells induced by thrombogenic and fibrinolytic factors: An in vitro cell culture model. Stroke 1995;26:265-270.
11. Lee KR, Betz AL, Keep RF, Chenevert TL, Kim S, Hoff JT: Intracerebral infusion of thrombin as a cause of brain edema. J Neurosurg 1995;83:1045-50.
12. Bendetowicz AV, Kai H, Knebel R, Caplain H, Hemker HC, Lindhout T, Béguin S: The effect of subcutaneous injection of unfractionated and low molecular weight heparin on thrombin generation in platelet rich plasma - A study in human volunteers. Thromb Haemost 1994;72:705-12.
13. Dagenais P, Théorêt J-F, Merhi Y, Latour J-G: Comparative study of unfractionated and a low molecular weight heparin (enoxaparin) as P-selectin inhibitors. FASEB J 1997;11:A311.
14. Nelson RM, Cecconi O, Roberts WG, Aruffo A, Linhardt RJ, Bevilacqua MP: Heparin oligosaccharides bind L- and P-selectin and inhibit acute inflammation. Blood 1993;82:3253-3258.
15. Gikakis N, Khan MD, Hiramatsu Y, Gorman JH, Hack CE, Sun L, Rao AK, Niewiarowski S, Colman RW, Edmunds LH: Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extra-corporeal circulation. Circulation 1996;14(suppl ii):341-346.
16. Bannon PG, Mi-Jurng K, Dean RT, Dawes J: Augmentation of vascular endothelial barrier function by heparin and low molecular weight heparin. Thromb Haemost 1995;73:706-712.
17. International Stroke Trial Collaborative Group: The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569-1581.